Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CASP1 | P29466 | 2/20 | 0.41 |
| ▸ | CASP7 | P55210 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | RORA | P35398 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | RORB | Q92753 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.39 |
| ▸ | AHR | P35869 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17274876 | 0.87 | MAPT (0.45) | MAPTLMNATSHRCASP1CASP7 | |
| SCHEMBL17274871 | 0.85 | POLB (0.56) | MAPTLMNATSHRCASP1CASP7 | |
| SCHEMBL17274758 | 0.85 | MAOA (0.54) | MAPTLMNATSHRCASP1CASP7 | |
| SCHEMBL18655578 | 0.84 | MAPT (0.53) | THRBMAPTLMNATSHRCASP1 | |
| SCHEMBL17274959 | 0.78 | MAPT (0.50) | THRBMAPTLMNATSHRCASP1 | |
| SCHEMBL13304767 | 0.73 | RORA (0.55) | THRBMAPTLMNAPOLBPGR | |
| SCHEMBL19271286 | 0.70 | TUBB4A (0.53) | THRBMAPTTSHRMAPK1TDP1 | |
| SCHEMBL18655576 | 0.70 | MAPT (0.57) | MAPTLMNATSHRCASP1CASP7 | |
| SCHEMBL18655577 | 0.70 | MAPT (0.67) | MAPTLMNATSHRCASP1CASP7 | |
| SCHEMBL19271309 | 0.69 | PTGER4 (0.46) | MAPTLMNAPOLBMAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10456400-B2 | Aza-ellipticine analogs, methods of synthesis and methods of treatment | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2019-10-29 | — | — | US | claimed |
| EP-3145507-A1 | AZA-ELLIPTICINE ANALOGS, METHODS OF SYNTHESIS AND METHODS OF TREATMENT | Musc Foundation for Research Development (US) | 2017-03-29 | — | — | EP | claimed |
| WO-2015179218-A1 | AZA-ELLIPTICINE ANALOGS, METHODS OF SYNTHESIS AND METHODS OF TREATMENT | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2015-11-26 | — | — | WO | claimed |
| US-10456400-B2 | Aza-ellipticine analogs, methods of synthesis and methods of treatment | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2019-10-29 | — | — | US | disclosed |
| US-10456400-B2 | Aza-ellipticine analogs, methods of synthesis and methods of treatment | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2019-10-29 | — | — | US | disclosed |
| US-20170081328-A1 | AZA-ELLIPTICINE ANALOGS, METHODS OF SYNTHESIS AND METHODS OF TREATMENT | MEDICAL UNIVERSITY OF SOUTH CAROLINA | 2017-03-23 | — | — | US | disclosed |
| US-20170081328-A1 | AZA-ELLIPTICINE ANALOGS, METHODS OF SYNTHESIS AND METHODS OF TREATMENT | MEDICAL UNIVERSITY OF SOUTH CAROLINA | 2017-03-23 | — | — | US | disclosed |
| US-20170081328-A1 | AZA-ELLIPTICINE ANALOGS, METHODS OF SYNTHESIS AND METHODS OF TREATMENT | MEDICAL UNIVERSITY OF SOUTH CAROLINA | 2017-03-23 | — | — | US | disclosed |
| WO-2015179218-A1 | AZA-ELLIPTICINE ANALOGS, METHODS OF SYNTHESIS AND METHODS OF TREATMENT | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2015-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081328-A1 | AZA-ELLIPTICINE ANALOGS, METHODS OF SYNTHESIS AND METHODS OF TREATMENT | AZI2, DNMT1, TET3 | THRB 3977/4885MAPT 3584/4885LMNA 2595/4885 |
| US-10456400-B2 | Aza-ellipticine analogs, methods of synthesis and methods of treatment | AZI2, DNMT1, TET3 | THRB 3977/4885MAPT 3584/4885LMNA 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.